Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Raymond James Maintains Outperform on Intercept Pharmaceuticals, Raises Price Target to $26

Raymond James analyst Steven Seedhouse maintains Intercept Pharmaceuticals (NASDAQ:ICPT) with a Outperform and raises the price target from $23 to $26.
byBenzinga Newsdesk
August 4, 2022
1 minute read
Total
0
Shares
0
0
0
0
0
0

Raymond James analyst Steven Seedhouse maintains Intercept Pharmaceuticals (NASDAQ:ICPT) with a Outperform and raises the price target from $23 to $26.

 
Total
0
Shares
Share 0
Tweet 0
Share 0
Share 0
Share 0
Share 0
Related Posts
Read More

Why Citizens Financial Shares Are Sliding Today

By Lekha Gupta
January 17, 9:31 AM
Citizens Financial Group reported a 10% YoY revenue dip in Q4 FY23, totaling $1.99B, missing analyst estimates. Despite a 38% YoY drop in adjusted net income to $426M, the CEO remains optimistic about strategic initiatives. CFG's decision to halt share repurchases in Q4 and an expected 6%-9% YoY decline in net interest income for FY24 draw attention.

CFG